ACQUISITIONS and MERGERS

These acquisitions mark a pivotal milestone in Innovia Medical’s continued growth, reinforcing its commitment to building a globally integrated platform of specialty surgical solutions.

The acquisition significantly broadens LICORbio’s electrophoresis offerings, allowing the company to deliver an end-to-end workflow with an expanded suite of products tailored to the evolving needs of proteomics researchers worldwide.

SpringWorks immediately adds revenue and accelerates mid- to long-term growth for Merck KGaA, Darmstadt, Germany’s Healthcare business sector. Acquisition marks the formation of a rare tumor business for Merck KGaA, Darmstadt, Germany including SpringWorks’ portfolio and pimicotinib. SpringWorks’ rare tumor portfolio includes Ogsiveo, a first-in-disease systemic therapy for adults with desmoid tumors and Gomekli a first and only approved therapy for adults and children with NF1-PN.

Bioness Medical further expands pipeline of next-generation robotics offerings for Neuro Rehab.

This strategic move underscores the Sun Nuclear commitment to leverage cutting-edge technology to improve treatment outcomes on behalf of their customers.

“Renal denervation for hypertension is an exciting medical advancement for the millions of patients it may help and is supported by positive results from contemporary clinical trials and ongoing research,” said Lance Bates, senior vice president and president, Interventional Cardiology Therapies, Boston Scientific. “We believe the addition of the differentiated, ultrasound-based TIVUS system can complement our expansive interventional portfolio with a minimally invasive therapy for patients with hypertension and provides opportunity for future advancements in this space.”